McKenna's Pharmacology for Nursing, 2e

982

Index

Gastrointestinal secretions, drugs affecting, 890–891, 896–913 adults, 899 children, 899 digestive enzymes, 896, 912–913 gastro-oesophageal reflux disease and ulcer disease, 897–912 antacids. See Antacids GI protectant, 896, 901, 909–910 histamine-2 antagonists. See Histamine-2 antagonists prostaglandins, 901, 910–912 proton pump inhibitors. See Proton pump inhibitors older adults, 899 Gastrointestinal system, 888–894 antiemetic agents. See Antiemetic agents function, 890–892 absorption, 891 digestion, 891 motility. See Gastrointestinal motility, drugs affecting secretion. See Gastrointestinal secretions, drugs affecting parasympathetic blockade, effects, 505 reflexes, 892–894 central, 893–894 local, 888, 892–893 structure, 889–892 Gastrointestinal toxicity, 87 Gate control theory of pain, 397, 399 Gefitinib, 219, 220, 221 Gelatin, absorbable, 767, 769, 770 Gemcitabine, 200, 201, 203

Ginkgo, 205, 965 Ginseng, 471, 582, 965 Glands, 512–515

oral hypoglycaemic agents, 586–587, 588–591 care considerations, 590–591 stress and, 577 sulfonylureas, 573, 585–588 adverse effects, 588 contraindications and cautions, 588 drug–drug interactions, 588 first generation, 587 pharmacokinetics, 588 second generation, 587 therapeutic actions and indications, 587–588 Glycerol, 920 Glyceryl trinitrate, 716–719 Glycogenolysis, 455, 457 Glycopyrrolate, 501, 503 Glycosuria, 572, 575 Glycosylated haemoglobin, 572, 576 Gold compounds, 252–253 adverse effects, 252 contraindications and cautions, 252 drug–drug interactions, 253 pharmacokinetics, 252 therapeutic actions and indications, 252 therapeutic effect, 5 Gold sodium thiomalate, 252, 253 Goldenrod leaves, 965 Goldenseal, 471, 965 Golgi apparatus, 72, 75 Golimumab, 265, 266 Gonadotropin-releasing hormone (GHRH), 522 Goserelin, 212, 214, 523, 524 Gotu kola, 965 Granisetron, 932, 934 Grape seed extract, 965 Green tea leaf, 965 Griseofulvin, 151, 153, 155 Growth hormone agonists, 521, 525–528 adverse effects, 527 care considerations, 527–528 contraindications and cautions, 527 drug–drug interactions, 527 administration, 718 Glycogen, 572, 574 Gram-negative bacteria, 90, 91 Gram-positive bacteria, 90, 91 therapeutic actions and indications, 526 Growth hormone antagonists, 528–530 adverse effects, 529 care considerations, 529–530 contraindications and cautions, 528–529 drug–drug interactions, 529 pharmacokinetics, 528 therapeutic actions and indications, 528 Growth hormone therapy, 526 Guaifenesin, 842, 857–858 new delivery system, 527 pharmacokinetics, 527

Glatiramer acetate, 263, 264 Glibenclamide, 573, 586–588

Gliclazide, 586, 587 Glimepiride, 586, 587 Glipizide, 586, 587 Glomerulus, 794, 796

glomerular filtration, 15, 23, 797 Glucagon, 572, 573, 575, 589–592 Glucagon-like polypeptide-1, 572, 573, 574, 586, 588–589 Glucocorticoids, 536, 539–545 adverse effects, 543 care considerations, 544–545 contraindications and cautions, 543 children, 543 elderly people, 543 drug–drug interactions, 543 duration of effect, 539 pharmacokinetics, 540, 543 routes of administration, 544 therapeutic actions and indications, 540 Glucosamine, 965 Glucose (generic), 806, 814 Glucose levels, controlling, 572–592, 809–810 adults, 574 alterations in glucose metabolism, 36–37 children, 574 diabetes mellitus, 572, 573, 576–578 cultural blood glucose variations, 577 fixed-combination oral agents, 589 glucose-elevating agents, 591–592 adverse effects, 592 care considerations, 592 contraindications and cautions, 591 drug–drug interactions, 592 pharmacokinetics, 591 therapeutic actions and indications, 591 glucose regulation, 573–576 glucagon, 575 insulin, 574–575 loss of blood glucose control, 575–576 miscellaneous factors, 575 pancreas, 573 insulin, 572–593 adverse effects, 581 care considerations, 582–583 contraindications and cautions, 579, 581 delivery, 580, 581 hyperglycaemia, 578 hypoglycaemia, 578 diabetes mellitus (type I), 584–585 drug–drug interactions, 581–582 name confusion, 579 pharmacokinetics, 579 therapeutic actions and indications, 579, 581

Gemeprost, 620, 622 Gemfibrozil, 738, 745 Gender drug effects and, 25, 26 General anaesthesia, 417–419 administration, 418–419 agents, 419–424

anaesthetic gases, 420, 421–422 barbiturate anaesthetics, 419–420 care considerations, 423–424 non-barbiturate anaesthetics, 420–421 volatile liquids, 420, 422–423

balanced, 418 induction, 419 maintenance, 419 recovery, 419 risk factors, 417–418

Generalised seizure, 352, 355 drugs for treating, 356–363 Generic drugs, 2, 5, 7, 9–10 cost considerations, 65–66 Generic name, 2, 5, 7 Genes, 72, 73 Genetic engineering, 2, 5 Genetic factors drug effects and, 25, 26 Gentamicin, 90, 95, 96, 957

Gentian violet, 157 Giardiasis, 163, 172 Gigantism, 521, 528 Ginger, 964

mechanisms, 575 older adults, 574

Guarana, 965 Guayusa, 965